Figure 3.
The distinctive recognition by patient T-cell LFA-1 of ligands ICAM-1, ICAM-2, and ICAM-3 after various integrin-activating protocols. (a) Ability of patient T cells to bind to immobilized ICAM-1, ICAM-2, and ICAM-3 either as untreated cells (white bars) or after treatment with PDBu (dotted bars), Ca2+ mobilizer thapsigargin (gray bars), and Mg2+/EGTA (black bars). Mg2+/EGTA is seen to induce patient T cells to bind to ICAM-2 and ICAM-3 but not to ICAM-1. (b) The binding of patient T cells (black bars) and control T cells (dotted bars) to ICAM-2 after treatment with 0.5 mM Mn2+ is prevented by chelation of divalent cations with EDTA and by CD11a function blocking MAB DF1524. (c) The binding of patient T cells (black bars) and control T cells (dotted bars) to ICAM-3 after 0.5 mM Mn2+ is prevented by chelation of divalent cations with EDTA and by CD18 function blocking MAB 60.3.